Zebra Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
$256K Buy
6,695
+653
+11% +$30.6K 1.28% 37
2022
Q4
$344K Buy
6,042
+785
+15% +$40.2K 1.2% 34
2022
Q3
$208K Sell
5,257
-1,620
-24% -$71.6K 0.79% 53
2022
Q2
$303K Buy
6,877
+610
+10% +$26.4K 0.89% 40
2022
Q1
$250K Sell
6,267
-494
-7% -$17.6K 0.57% 73
2021
Q4
$272K Sell
6,761
-2,493
-27% -$93.1K 0.44% 83
2021
Q3
$376K Sell
9,254
-96
-1% -$4.01K 0.46% 79
2021
Q2
$425K Sell
9,350
-1,009
-10% -$44.7K 0.5% 75
2021
Q1
$432K Buy
+10,359
New +$473K 0.48% 78
2019
Q4
Sell
-13,500
Closed -$211K 303
2019
Q3
$211K Buy
+13,500
New +$222K 0.23% 173

Other funds holding HALO

Zebra Capital Management's HALO Position: Q1 2023 in Review

Zebra Capital Management increased its Halozyme (HALO) stake by 11% in Q1 2023, buying an estimated $30.6K and bringing the position to 6,695 shares worth $256K. The position accounts for 1.28% of the portfolio, ranked #37.

Zebra Capital Management first reported a position in HALO in Q3 2019 and has held it in 10 quarters since. The position peaked at $432K in Q1 2021. 386 funds tracked by Wall St. Rank hold HALO as of Q1 2023.

  • Zebra Capital Management held 6,695 shares of Halozyme worth $256K as of Q1 2023.
  • Zebra Capital Management bought 653 Halozyme shares in Q1 2023, an estimated $30.6K.
  • Halozyme made up 1.28% of Zebra Capital Management's portfolio in Q1 2023, its #37 holding.
  • Zebra Capital Management first reported a position in Halozyme in Q3 2019 and has held it in 10 quarters since.
  • Zebra Capital Management's Halozyme position peaked at $432K in Q1 2021.
  • 386 funds tracked by Wall St. Rank held Halozyme as of Q1 2023.

Based on Zebra Capital Management's 13F filing for Q1 2023, filed 15 May 2023.